Fighter wrote:... but also had an asthma attack which required oxygen....
... I had become allergic to both the anti-viral and antibiotic which were part of the post treatment protocol...
...plus a severe asthma attack...
I would be careful about taking Campath as first therapy (you probably won´t get it anyway..).
There are severe side effects!
In the trial were about 200 people getting Campath - e.g. 25 % got thyroid problems, 3 patients got severe bleeding disorders, 1 patient even died!
The trial had to be cancelled.
But most articles conceal the severe side effects.
The manufacturer "Bayer" even claims:
The side effects are controllable."
That´s just cynical in my eyes.
I would never take this stuff, only if I were in a really bad condition.
I´m just wondering why ALL the media are full of the "news" (results have been available since 2006!)
Looks like a well planned huge campaign all over the world (good work, Bayer!!)
What have we learned from the alemtuzumab experience? The data convincingly demonstrate that intensive immunosuppression can dramatically reduce the accumulation of new inflammatory lesions and focal scarring and the rate of clinical relapse in pateients with recent-onset multiple sclerosis. The current study by Coles et al., combined with earlier pioneering studies by Alastair Compston and his colleagues using the alemtuzumab paradigm, highlights the value of very aggressive therapy instituted at the beginning of the disease process, a time when the majority of inflammatory damage is subclinical and disability is absent or mild in most patients. The authors suggest the possibility that early treatment may protect against the development of neurologic disability many years or decades later. In a larger sense, these data point the way toward a rethinking of therapy for mulitple sclerosis, akin to standard models of cancer therapy, in which an intensive induction is followed by a less-intensive maintenance regimen. Although the place of alemtuzumab in the armamentatrium of therapies for multiple sclerosis will ultimately be determined by its efficacy and safety during longer periods of observation, these thoughtful clinical investigations have advanced the field substantially by helping adress the relationship between the inflammatory phase of the disease and the degenerative phase, as well as the potential value of early aggressive therapy.
ursula wrote:How do they know that only patients with fresh ms can benefit? (I think they took only patients without treatment in the past - sure they were afraid of unforeseeable interactions)
ursula wrote:unfortunately, I only know an article in german..
Users browsing this forum: No registered users